In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication. Thanks largely to news of a crucial legal settlement, GSK (GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively bidding the company's shares up by 5.8% on the day, a performance that easily eclipsed the 0.7% rise of the benchmark S&P 500 index. $2.2 billion-plus in settlements That news concerns a discontinued version of GSK ...